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ApoptosisIt has long been observed that cancer cells rely more on glycolysis to generate ATP and actively use certain
glycolytic metabolic intermediates for biosynthesis. Hexokinase II (HKII) is a key glycolytic enzyme that plays
a role in the regulation of the mitochondria-initiated apoptotic cell death. As a potent inhibitor of hexokinase,
3-bromopyruvate (3-BrPA) is known to inhibit cancer cell energy metabolism and trigger cell death,
supposedly through depletion of cellular ATP. The current study showed that 3-BrPA caused a covalent
modiﬁcation of HKII protein and directly triggered its dissociation from mitochondria, leading to a speciﬁc
release of apoptosis-inducing factor (AIF) from the mitochondria to cytosol and eventual cell death. Co-
immunoprecipitation revealed a physical interaction between HKII and AIF. Using a competitive peptide of
HKII, we showed that the dissociation of hexokinase II from mitochondria alone could cause apoptotic cell
death, especially in the mitochondria-deﬁcient ρ0 cells that highly express HKII. Interestingly, the
dissociation of HKII itself did not directly affect the mitochondrial membrane potential, ROS generation,
and oxidative phosphorylation. Our study suggests that the physical association between HKII and AIF is
important for the normal localization of AIF in the mitochondria, and disruption of this protein complex by
3-BrPA leads to their release from the mitochondria and eventual cell death.© 2009 Elsevier B.V. All rights reserved.1. Introduction
In the 1920s Otto Warburg observed that liver tumor tissue
exhibited an increase in glycolytic activity, even in the presence of
oxygen. The phenomenon that tumor cells exhibit increased glycolysis
and rely more on this metabolic pathway to generate ATP under
aerobic conditions is known as the “Warburg effect” [1,2]. Such
increased aerobic glycolysis has since been observed in a variety of
cancer types. Although whether this metabolic switch in cancer cells
is a causal event in cancer development or merely a downstream
biochemical symptom of cancer is still a matter of debate, accumulat-
ing evidences seem to suggest that aerobic glycolysis is closely
associated with tumorigenesis and plays important roles in maintain-
ing the malignant behaviors of the cancer cells and promoting
metastasis. High levels of glycolysis seem to confer malignant cell
survival advantage in hypoxic or acidosis microenvironment during
the process of cancer development. This unique metabolic proﬁle of
cancer cells provides a biochemical basis for developing new
chemotherapeutic strategies targeting the glycolysis pathway in
cancer cells [3].
Various inhibitors affecting the key enzymes of the glycolysis
pathway have been identiﬁed. Among the glycolytic inhibitors
currently under development for potential use in cancer treatment,1 713 834 6084.
).
ll rights reserved.3-BrPA exhibits promising anticancer activity both in vitro and in vivo
[4]. Although the details in the mechanisms of action responsible for
the anticancer activity of 3-BrPA remain to be fully elucidated, this
compound is believed to inhibit HKII and prevent glucose from
entering the glycolytic pathway [4]. It should be noted, however, that
3-BrPA is a small molecule and chemically reactive. This compound
may potentially affect multiple targets in the cells.
Hexokinase (ATP: D-hexose 6-phosphotransferase) is a key
enzyme that catalyzes the ﬁrst step in the glycolysis pathway. This
enzyme transfers a phosphate group from ATP to glucose to form
glucose-6-phosphate. In human cells, there are four isoforms of
hexokinase (I–IV). Despite their overall structural similarity, these
isoforms differ in their expression patterns, subcellular localizations,
and catalytic/regulatory properties. In normal tissue, hexokinase I is
mainly expressed in the brain and kidney, while hexokinase II is found
mainly in the heart and skeletal muscle. The type III isozyme is found
in virtually all tissues but is expressed at low levels. Hexokinase IV
(glucokinase) is mainly expressed in liver and the islets of langerhans.
Interestingly, hexokinase III exhibits perinuclear localization, but its
biological function still remains unclear. All four isoforms are believed
to play distinct roles in metabolism and affect cell fates [8,9]. Of note,
hexokinase I and II are found to be able to bind to mitochondria
through their interaction with VDAC (voltage dependent anion
channel), and this association appears important for the homeostasis
of mitochondria [10,11]. Additionally, such mitochondrial association
has been reported to inﬂuence the enzyme kinetics of hexokinase [12].
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regulation of the key glycolytic enzymes including hexokinase.
Interestingly, the percentage of hexokinase binding to the mitochon-
dria is also signiﬁcantly increased in cancer cells. For instance, in AS-
20D liver tumor cells, the hexokinase protein level (mainly HKII) was
found to be more than 500 times higher than in normal liver cells,
which mainly express hexokinase IV instead. Furthermore, around
80% of hexokinase II is associated with mitochondria [13]. Due to the
frequent up-regulation of HKII in cancer cells and its important role in
glycolytic pathway, this enzyme seems to be an attractive target for
anticancer drug development.
2. Materials and methods
2.1. Materials
3-BrPA, H2O2, clotrimazole (CTZ), 2-Deoxyglucose (2-DG), cyclos-
porin A (CsA), and rotenone were purchased from Sigma-Aldrich (St.
Louis, MO). 3-BrPA was dissolved in water and neutralized with
Na2CO3 immediately before use. Goat polyclonal anti-hexokinase II
antibody was purchased from Santa Cruz Biotechnology (Santa Cruz,
California). Rabbit polyclonal anti-AIF was purchased from Chemicon
(Temecula, CA). Cytochrome c monoclonal antibody (Clone/PAD:
7H8.2C12) was purchased from Invitrogen Corporation (Carlsbad,
California). Immunoprecipitation Starter Pack was purchased from GE
healthcare life sciences (Piscataway, NJ).
2.2. Cell culture
Human leukemia cells lines (HL-60) and lymphoma cell line (Raji)
were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated FBS at 37 °C with 5% CO2. Human colon cancer cells
(HCT116 p53+/+ and HCT116 p53−/−) were cultured in McCoy's 5 A
medium supplemented with 10% FBS. The mitochondrial defective
clones (ρ0 cells) HL-60/C6F, Raji/C2, Raji/C6 were maintained in
RPMI 1640 supplemented with 10% fetal bovine serum, 1 mmol/L
sodium pyruvate, 50 mmol/L uridine, and 2.7% glucose. The ρ0 clone
HCT116+/+/c15 was maintained in McCoy's 5 A medium supple-
mented with 10% fetal bovine serum, 1 mmol/L sodium pyruvate,
50 mmol/L uridine, and 2.7% glucose.
2.3. Cytotoxicity assay
Apoptotic or necrotic cell death was determined by ﬂow cytometry
analysis of cells double-stained with annexin-V-FITC and propidium
iodide (PI). After drug treatment, cells were collected and re-suspended
in annexin-V binding buffer, then stained with annexin-V-FITC for
15 min at room temperature, and subsequently stained with PI. The
samples were then analyzed using a FACS Calibur ﬂow cytometer.
2.4. Measurements of mitochondria membrane potential and cellular ROS
Rhodamine-123 is a cell-permeable, cationic, green-ﬂuorescent
dye that can be readily sequestered by active mitochondria in
proportion to the mitochondrial membrane potential. This compound
has been commonly used for monitoring membrane potential and
apoptosis. Rhodamine 123 (1 μM) was added into cell culture and
incubated for 30 min before sample collection. After washing with
PBS, the samples were analyzed by ﬂow cytometry as described
previously [5]. Cellular superoxide level was measured by hydro-
ethidine by ﬂow cytometry [5].
2.5. Measurement of mitochondria respiration activity
To determine cellular oxygen consumption, 5–10million cells were
suspended in 1 ml culture medium, which had been pre-saturatedwith oxygen (21%) by exposure to air in a 37 °C water bath. The cell
suspension was sealed in a respiration chamber, and the oxygen
concentration in the medium was monitored by a Clark-type oxygen
electrode disc (Oxytherm, Hansatech Instrument, Cambridge, UK).
The oxygen consumption rates were plotted on a graph and calculated
as described previously [5].
2.6. Western blot analysis
Whole cells or mitochondrial fractions were lysed in 1×SDS
sample buffer and resolved by electrophoresis using SDS-PAGE and
transferred to nitrocellulose membranes. The membranes were
probed with primary antibodies overnight, and then incubated with
appropriate horseradish peroxide-conjugated secondary antibodies
for 3 h followed by detection with a SuperSignal Enhanced
Chemiluminescence kit (Pierce, Rockford, IL). For sequential blotting,
the membranes were stripped with Stripping Buffer (Pierce) and
reprobed with proper antibodies.
2.7. Co-immunoprecipitation
Co-immunoprecipitation experiments were performed using the
Immunoprecipitation Starter Pack according to the manufacture's
protocol (GE healthcare life sciences). 1×107 cells were lysed in NP40
lysis buffer supplemented with PI cocktail, and co-immunoprecipita-
tion was carried out using hexokinase II antibody. Primary antibody
was incubated for 3 h at 4 °C. Protein-A beads were added and
incubated for 1 h before the samples were collected and the washed.
Proteins precipitated by protein-A beads were boiled and eluted in
1×SDS-PAGE sample buffer for 5 min. Samples were analyzed by
Western blotting using anti-hexokinase II and AIF antibodies.
2.8. Isolation of mitochondria and protein fractionation
Mitochondria of human leukemia cell line HL60 was isolated by
conventional differential centrifugation as described previously [6].
Brieﬂy, cells were harvested, washed once with cold PBS, and re-
suspended in a buffer containing 10mM Tris–HCl, pH 7.5, 10 mMNaCl,
1.5 mM MgCl2, 1 mM EDTA, 70 mM sucrose, 210 mM mannitol, and
protease inhibitors. After incubating in an ice-bath for 10 min, the cell
suspension was homogenized with 15 strokes in a 2 ml glass
homogenizer. The samples were centrifuged twice at 1500×g at 4 °C
for 5 min to remove nuclei and cell debris. The supernatants were
centrifuged at 15,000×g for 15 min to separate the mitochondrial
fraction and cytosolic fraction. The mitochondria-enriched fractions
were suspended in 50 μl KCl based respiratory buffer (150 mM KCl,
25 mM NaHCO3, 1 mM MgCl2, 3 mM KH2PO4, 20 mM HEPES, pH 7.4)
[7]. After treatment with compounds such as 3-BrPA, CTZ and
Glucose-6-P for 30 min at room temperature, the mitochondria
fractions were then pelleted at 16,000×g for 10 min. The pellet and
resulting supernatant were separated on 10% SDS polyacrylamide gel
and immunoblotted for Hexokinase II, AIF, cytochrome c and HSP 60
using appropriate antibodies.
3. Results and discussion
3.1. Upregulation of HK II in cancer cells with mitochondrial respiratory
defect
To access the role of HKII in promoting the survival of cancer cells
with mitochondrial respiratory defects, we ﬁrst compared the
expression levels of HKII protein in cells with competent mitochon-
drial function and cells deﬁcient in respiration (ρ0 cells) derived from
the same tissue origins. Due to the inability to respire, the ρ0 cells
solely depend on the glycolytic pathway to generate ATP. As shown in
Fig. 1, the ρ0 cells derived from HCT116 (p53+/+), HL-60, and Raji cells
Fig. 1.Overexpression of HKII in ρ0 cells and its localization to the mitochondria. (A)
Comparison of HKII protein expression in HCT116 (p53+/+) cells, their ρ0 clone
(HCT116+/+C15) andHCT116 (p53−/−) cells. Approximately 106 cellswere collected and
lysed in 1×SDS-PAGE sample buffer.Mitochondria from5×106 cells of each cell linewere
isolated by differential centrifugation and lysed in 1×SDS-PAGE sample buffer. Lysates
were immunoblotted for HKII and HSP60. (B) Lysates of whole cell and mitochondria
fractions of HL-60 cells and their ρ0 derivatives HL-60/C6F cells were prepared, and
immunoblotted for HKII and HSP60. (C) Lysates of whole cell andmitochondria fractions
of Raji cell, their ρ0 derivatives Raji C2, C6, and Raji cells treatedwith 1 nM rotenone (Rot)
for 12 h were prepared as above, and then immunoblotted for HKII and HSP60. The level
of hexokinase II was normalized to HSP60 using densitometry analysis.
Fig. 2. Covalent modiﬁcation of HKII protein induced by 3-BrPA. (A) HL-60 cells were
treated with 100 μM 3-BrPA for 1, 3 and 5 h. Cells were collected and lysates were
immunoblotted for HKII and HSP60. (B) HL-60 cell lysates were incubated with 100 μM
3-BrPA at room temperature for 10 min, two of the samples were mixed with 1 mMDTT
5min before (Pre) or after (aft) addition of 3-BrPA. Another samplewas boiled for 5min
at 95 °C to denature the proteins before treatment with 3-BrPA. Lysates were
immunoblotted for HKII and HsP60.
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respective parental cells. Interestingly, substantially more HKII
proteins were located in the mitochondrial fraction of the ρ0 cells
(Fig. 1A, B). Chemical inhibition of mitochondrial respiration by the
electron transport chain inhibitor rotenone also caused the transloca-
tion of HKII to the mitochondria (Fig. 1C). Hypoxia, which suppresses
mitochondrial respiration, also has a similar effect on HKII (data not
shown).
Emerging evidence suggests that the upregulation of HKII and its
mitochondrial localization may not only make it easier for the cells to
use ATP generated from mitochondria for phosphorylation of glucose,
but may also have anti-apoptotic effects due to its interactionwith the
mitochondria. However, the detailed mechanisms still remain to be
investigated. One possibility could be that HKII interacts with the Bcl-
2 familymembers, for example through competingwith Bax to bind to
VDAC, to stabilize the MPTP (Mitochondrial permeability transition
pore) and mitochondrial homeostasis [14]. Furthermore, because the
product of hexokinase, glucose-6-phosphate is a common metabolic
intermediate for both the glycolysis and the pentose phosphate
pathways, inhibition of the hexokinase enzyme activity can have
profound effect on cellular metabolism including mitochondria
oxidative phosphorylation. Due to the important roles of HKII in
both cancer cell metabolism and apoptosis, it is reasonable to
speculate that this molecule may serve as a potential target for
chemotherapy.
3.2. 3-Bromopyruvate covalently modiﬁes HKII and causes its
dissociation from mitochondria
Several chemicals including 2-deoxyglucose (2-DG), 3-bromopy-
ruvate (3-BrPA), 5-thioglucose, clotrimazole, lonidamine, mannohep-tulose and glufosfamide, have been shown to affect the activity of HKII
[3]. 3-BrPA (3-bromopyruvatic acid, Br-CH2-CO-COO-) is an analogue
of pyruvate and an alkylating reagent that can react with the free SH
groups of cysteine residues in certain proteins. This compound has
been used for the treatment of the protozoan parasite Trypanosoma
brucei, which generates ATP exclusively through glycolysis. According
to early studies, the target of 3-BrPA is the trypanosomal glyceralde-
hyde-3-phosphate dehydrogenase [15]. Recent studies demonstrated
that 3-BrPA is a potent inhibitor of hexokinase enzyme, and can inhi-
bit both glycolysis and mitochondrial oxidative respiration in VX2
tumor model [4]. Importantly, 3-BrPA exhibited promising in vivo
anticancer activity in the rabbit model of advanced hepatocellular
carcinoma (AS-30D) without signiﬁcant toxic side effect on normal
liver tissue [16].
Previous studies showed that 3-BrPA can cause severe depletion of
cellular ATP pool and induce cell death in various cancer cell lines [17].
Incubation of HL-60 cells with 100 μM 3-BrPA for 12 h caused up to
80% reduction of cellular ATP and signiﬁcant cell death, which was
associated with cytochrome c release and activation of caspase 3.
Additionally, 3-BrPA was found to be more effective against cells
under hypoxic conditions and ρ0 cells, which are less sensitive to
traditional chemotherapeutic agents such as doxorubicin, ara-C, and
Taxol [17]. However, the detailed molecular mechanism by which 3-
BrPA inhibits glycolysis and induces cell death still remains to be
investigated.
Western blot analyses of protein extracts from cells treated with 3-
BrPA revealed an interesting change in the electrophoresis mobility of
HKII. As shown in Fig. 2, therewas a time-dependent up-shifting of the
HKII band after cells were incubated with 3-BrPA. This mobility
alterationwas not due to electrophoresis artifacts, since other proteins
such the HSP60 and actin on the same gel did not exhibit a similar up-
shift. Because 3-BrPA is an alkylating reagent capable of reacting with
the -SH groups of the cysteine residues, it is likely that this up-shift
reﬂects a covalent modiﬁcation on cysteine residues in HKII protein.
Fig. 3. Release of HKII and AIF frommitochondria induced by 3-BrPA. (A) 107 HL-60 cells
were treated with 100 μM 3-BrPA for 3–6 h as indicated, mitochondria were isolated by
differential centrifugation and lysates were immunoblotted for AIF, cytochrome c
(Cyt c) and HSP60. (B) Mitochondria fractions were isolated from HL-60 cells and
resuspended in 50 μl KCl-based respiratory buffer. Mitochondria were treated
separately with 20 μM CTZ, 1 mM glucose-6-phosphate, 200 μM 3-BrPA for 30 min at
room temperature. The supernatants and mitochondria pellets were separated by
centrifugation at 16,000×g for 10min. Lysates were immunoblotted for HKII and HSP60.
(C) Themitochondrial fractions of HL-60 cells were incubated with H2O2 and 3-BrPA for
30 min at room temperature. The supernatants and mitochondria pellets were
separated by centrifugation. Lysates were immunoblotted for cytochrome c and AIF.
(D) HCT116 (p53+/+) cells were treatedwith 100 μM3-BrPA for 5 h, and cells were then
lysed in NP-40 lysis buffer containing protease inhibitors cocktail. Co-immunoprecipi-
tation was carried out using HKII antibody. The IP products were immunoblotted for
HKII and AIF.
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using DTT to interfere with the reaction between 3-BrPA and -SH of
cysteine. Cell lysates of HL-60 cells were incubated with 100 μM 3-
BrPA at room temperature with 1 mMDTT being added before or after
the addition of 3-BrPA. Another sample was heated at 95 °C for 5 min
to denature the proteins before incubation with 3-BrPA. As shown in
Fig. 2B, the sample treated 3-BrPA alone showed a signiﬁcant up-shift
compared with control sample, and pre-incubation with DTT or pre-
denature by heating prevented 3-BrPA-induced band shift. This data
suggests that 3-BrPA may indeed target the sulfhydryl group of
cysteine residues in HKII. Because the estimation of molecular weight
by electrophoresis in SDS-PAGE gel could not accurately determine the
increments of band small shifting caused by different numbers of 3-
BrPA molecules, the exact number of 3-BrPA molecules bound to each
HKII protein is still unclear. The use of more accurate methods such as
mass spectrometry analysis should provide useful information to
calculate the number of 3-BrPA molecules bound to HKII. This
chemical modiﬁcation is likely redox sensitive and may depend on
certain conformation of HKII. It would be interesting to further
determine which speciﬁc cysteine residues in HKII are targets of 3-
BrPA, and how this modiﬁcation affects hexokinase II enzyme activity
and functions. Experimental strategies based on site-speciﬁc muta-
tion, immunoprecipitation, and mass spectrometry may help to
answer this important question.
Previous studies showed that 3-BrPA can induce cell death through
the mitochondria-mediated intrinsic apoptotic pathway, which is
coupled with the release of cytochrome c from mitochondria to
cytosol leading to activation of the caspase cascade. Also it is known
that the mitochondria-associated HKII is involved in the regulation of
apoptosis. However, the exact role of HKII in 3-BrPA-induced cell
death remains unclear. To investigate the effect of 3-BrPA on HKII
interaction with the mitochondria in whole cells, mitochondria-
enriched fractions from 3-BrPA-treated cancer cells were isolated by
differential centrifugation, and the release of mitochondrial proteins
was analyzed by western blot analysis. As shown in Fig. 3A,
mitochondria isolated from HL-60 cells treated with 100 μM 3-BrPA
exhibited a signiﬁcant loss of HK II with concurrent loss of Apoptosis
inducing factor (AIF). Interestingly, there was no signiﬁcant loss of
cytochrome c from the mitochondria under the conditions (100 μM 3-
BrPA, 3–6 h). Similar results were also observed in HCT116 and Raji
cells (data not shown).
Although the release of HKII from the mitochondria could simply
be a subsequent event of apoptosis induced by 3-BrPA, the rapid
release of HKII and its up-shift suggests that 3-BrPA may have a direct
effect on he mitochondrial-associated HKII. To test this possibility, an
in vitro assay using isolated mitochondria from HL60 cells was
performed. Mitochondria isolated from HL-60 cells were resuspended
in a buffer containing KCl, and incubated with clotrimazole (CTZ),
glucose-6-phosphate, or 3-BrPA to test the direct effect of these
compounds. The rationalewas that proteins released from the isolated
mitochondria would be in the supernatant and could be separated
from the mitochondrial-associated proteins by centrifugation. CTZ is
known to dissociate HKII from mitochondria through targeting the
interaction of HKII and VDAC, whereas glucose-6-phosphate is a
known inhibitor of HK [18,19]. These two compounds were used as
controls for comparison with 3-BrPA. The supernatant and mitochon-
dria pellets were separated through centrifugation and immuno-
blotted for HKII and HSP60. As shown in Fig. 3B, 3-BrPA not only
caused the up-shift of HKII, but also led to the release of HKII from the
mitochondria. It should be noted that the amount of HKII released
from the mitochondria seemed only moderate, probably due to the
short-time (30 min) incubation of 3-BrPAwith the isolated mitochon-
dria. When whole cells were incubated with 3-BrPA for a longer time
(6 h), there was a substantial amount of HKII release from the
mitochondria (Fig. 3A, lane 3). Similar experimentswere performed to
test the release of AIF and cytochrome c. As shown in Fig. 3B, C,addition of 50 μM 3-BrPA caused the release of HKII and AIF from
mitochondria, but the release of cytochrome cwas again undetectable,
consistent with the observation in Fig. 3A.
The preferential release of AIF, which is larger than cytochrome c in
molecular weight, suggests that AIF may be physically associated with
HKII, which can be disrupted by 3-BrPA. This possibility was tested by
co-immunoprecipitation experiments. HCT116 colon cancer cells
treated with 3-BrPA were lysed in NP-40 lysis buffer and co-
immunoprecipitation was carried out using anti-HK antibody. The IP
pulled-down samples were immunoblotted for both hexokinase II and
AIF. As shown in Fig. 3D, there was a detectable physical interaction
between HKII and AIF, and treatment of cells with 100 μM 3-BrPA
signiﬁcantly disrupted such interaction.
AIF is considered as a killer protein, which plays a major role in
caspase-independent mitochondria-mediated cell death. Once
released from the mitochondria, AIF may translocate to the nucleus
and induce DNA condensation and fragmentation. AIF is also known as
a redox molecule with enzyme similar to NADH oxidase, which
generates ROS through oxidization of NADH. It has been reported to be
Fig. 4. Release of HKII and AIF frommitochondria and caused cell death induced byN-HK
II peptide. (A) Experimental scheme. (B) HL-60 cells were treatedwith 10–30 μMN-HK II
peptide. Culturemediumwas replacedwith RPMImediumwithout serum for treatment
with 10 or 30 μMN-HK II peptide for 1 h. Then the serum-freemediumwas replacedwith
RPMI medium with 10% FBS and incubated for additional 2 h. Mitochondria fractions
were isolated and immunoblotted for HKII, AIF, and cytochrome c. (C) HL-60 cells were
treatedwith 2,10, and 20 μMN-HK II peptide and scrambled control peptide as described
above. Cytotoxicity was analyzed by annexin-V/PI staining and ﬂow cytometry analysis.
(D) HL-60 cells and their ρ0 clone HL-60/C6F were treated with 2,10, and 20 μMN-HK II
peptide as described above. Cells were collected and analyzed by annexin-V/PI staining
to determine cytotoxicity.
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cells seemed to have a lower level of ROS and were more sensitive to
oxidant-induced apoptosis [20]. However, the biological function of
AIF in the mitochondria and its regulation remain unclear. The co-
immunoprecipitation experiments indicate that hexokinase II may
form a complex with AIF and their interaction can be disrupted by 3-
BrPA treatment. It would be interesting to test if HKII can regulate
mitochondria function or redox level through its interaction with AIF.
3.3. Dissociation of HKII from the mitochondria triggers cancer cell death
The ﬁnding that 3-BrPA treatment caused a release of HKII and AIF
from the mitochondria led us to hypothesize that the dissociation of
HKII from mitochondria may play an important role in 3-BrPA-
induced cell death. To test this possibility, a cell permeable N-terminal
peptide of hexokinase II (N-HK II peptide) was synthesized based on
the sequence of the N-terminal 15 amino acids of HKII, which is
essential for associationwith mitochondria [18]. Once N-HKII is inside
the cells, the peptide can cause dissociation of HKII frommitochondria
through direct competition [18].
Fig. 4A illustrates the experimental procedures for testing the
ability of N-HK II peptide to cause HKII dissociation frommitochondria
and trigger cell death. In order to avoid the interference from FBS on
peptide uptake, RPMI medium without FBS was use during the 1-h
incubationwith N-HK II peptide. After treatment with 10–30 μMN-HK
II peptide, mitochondria were isolated from HL-60 cells and
immunoblotted for HKII, AIF, and cytochrome c by western blotting.
The data indicated that the N-HKII peptide treatment induced the
release of HKII and AIF (Fig. 4B), similar to the action of 3-BrPA. The
cytotoxicity of N-HK II peptide in HL-60 cells was analyzed by
annexin-V/PI staining followed by ﬂow cytometry analysis. A
scrambled peptide was used as control. As shown in Fig. 4C, although
the control scrambled peptide showed some cytotoxicity, the N-HK II
peptide induced substantially more cytotoxic effect compared to the
scrambled peptide at each concentration tested. This suggests that the
dissociation of HKII from the mitochondria might play a role in
promoting 3-BrPA-induced cell death. Interestingly, a 3-h incubation
with 10 μMN-HK II peptide caused a substantial loss of HK II from the
mitochondria without much release of AIF at this early time point,
whereas a higher concentration of N-HK II peptide (30 μM) caused a
substantial release of both HK II and AIF from the mitochondria (Fig.
4B). This data together with the dose-dependent cytotoxic action of N-
HK II peptide in HL-60 cells (Fig. 4C) suggests that the release of AIF
subsequent to HK II dissociation from the mitochondria may be an
important event in the cell death process.
Previous studies showed that ρ0 cells have higher levels of
glycolysis and are more sensitive to glycolysis inhibitors [17]. Data
shown in Fig. 1 also suggest that HKII were overexpressed in ρ0 cells
and largely localized to the mitochondria. This may in part explain the
increase in glycolysis and resistance to chemotherapy in ρ0 cells. Since
ρ0 cells have more HKII associated with mitochondria, we then tested
whether ρ0 cells are more sensitive to N-HK II peptide treatment. A
shown in Fig. 4D, the HL-60 ρ0 cells (C6F) with higher level of
hexokinase II were likely to be more sensitive to N-HKII peptide
treatment compared to the parental HL-60 cells.
3.4. Effect of 3-BrPA and N-HK II peptide on mitochondrial
transmembrane potential
The loss of mitochondrial transmembrane potential is considered
as a marker of mitochondria permeability transition and an early
event of mitochondria-initiated cell death. Rhodamine-123 is a cell-
permeable, cationic, green-ﬂuorescent dye that can be readily
sequestered by active mitochondria, and has been commonly used
to monitor mitochondrial transmembrane potential and apoptosis.
Since HKII can be associated with VDAC, a major component of theMPTP, and 3-BrPA is able to cause cellular ATP depletion and the
dissociation of HKII from the mitochondria, it is reasonable to
speculate that 3-BrPA may affect mitochondrial transmembrane
potential through its ability to cause dissociation of HKII from the
organelle. To test if 3-BrPA can cause mitochondria permeability
transition in living cells, HL-60 cells and its ρ0 derivate HL-60/C6F
cells were treated with 3-BrPA for various times and rhodamine-123
was used to monitor the change of membrane potential. 3-BrPA can
cause a loss of membrane potential in a time-dependent manner in
both HL-60 and their ρ0 derivatives, with the ρ0 cell being more
sensitive to 3-BrPA (Fig. 5A, B). Cyclosporin A (CsA) is known to
suppress the mitochondrial permeability transition through inter-
Fig. 5. Effect of 3-BrPA and N-HK II peptide on mitochondrial transmembrane potential. (A) HL-60 cells were treated with 100 μM 3-BrPA for 5–9 h, the mitochondrial membrane
potential were analyzed by ﬂow cytometry using rhodamine-123 as ﬂuorescent dye (1 μM for 1 h). (B) HL-60 ρ0 (C6F) cells were treated with 100 μM 3-BrPA for 5–9 h, the
mitochondrial membrane potential were analyzed by ﬂow cytometry using rhodamine-123 as ﬂuorescent dye. (C) HL-60 cells were treated with 100 μM 3-BrPA for 5 h with or
without pretreatment of 5 μM CsA (5 h). Mitochondrial transmembrane potential was analyzed by using rhodamine-123. (D) HL-60 cells were treated with 5 mM 2-DG or 100 nM
rotenone for 12 h. Mitochondrial transmembrane potential was measured using rodamine-123. (E) HL-60 cells were incubated with 10 and 30 μM N-HK II peptides as described in
Fig. 4. Mitochondrial membrane potential was measured using rodamine-123. (F) HL-60/C6F cells were treated with 100 μM 3-BrPA alone or in combination with 2 μM N-HK II
peptide for 5 h. Rhodamine-123 was used to monitor the loss of mitochondrial transmembrane potential.
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whether the permeability transition caused by 3-BrPA can be
prevented by CsA, HL-60 cells were pretreated with 5 μM CSA for
5 h, and then treated with 100 μM 3-BrPA. As shown in Fig. 5C, 3-BrPA
caused a signiﬁcant loss of membrane potential and CsA showed no
protective effect. This indicates that 3-BrPA-induced mitochondria
permeability transition may not involve cyclophilin D. The effects of
mitochondrial respiration inhibitor rotenone and glycolysis inhibitor2-DG were also tested (Fig. 5D). Both inhibitors also caused the loss of
mitochondrial membrane potential, and the 2-DG inhibitory effect
was similar to 3-BrPA.
Whether the dissociation of hexokinase II from the mitochondria
leads to the loss of membrane potential still remained unclear. In
order to address this question, the effect of N-HKII peptide on
mitochondrial membrane potential was tested. HL-60 cells were
treated with 10 and 30 μM peptides for 3 h using the same procedures
Fig. 6. Effect of N-HK II peptide and rotenone on mitochondrial respiration and ROS
generation. (A) HL-60 cells were pre-treated with 3, 10 and 30 μMN-HK II peptide for a
total of 3 h as described in Fig. 4A. Oxygen consumption of 107 cells was measured at
37 °C using a Clark-type oxygen electrode. (B) HL-60 cells were treated with 3, 10 and
30 μMN-HK II peptide and superoxide levels weremeasured by ﬂow cytometry analysis
using hydroethidine as a ﬂuorescent dye. (C) HL-60 cells were pre-treated with 100 nM
rotenone for 9 h, and then incubated with 10 μM N-HK II peptides for additional 3 h.
Superoxide levels were measured by using hydroethidine.
559Z. Chen et al. / Biochimica et Biophysica Acta 1787 (2009) 553–560used above. Interestingly, although N-HK II peptide caused dissocia-
tion of hexokinase II from mitochondria and induce cell death, this
peptide alone exhibited no effect on membrane potential (Fig. 5E).
This was consistent with the observations by other research group
[21]. Interestingly, when cells were treated with N-HK II peptide in
combination with 3-BrPA, the depolarization was signiﬁcantly
enhanced. As shown in Fig. 5F, when HL-60/C6F cells were treated
with 100 μM 3-BrPA in combination with 2 μMN-HKII peptide for 5 h,
massive collapse of membrane potential was observed. These data
suggested that N-HK II peptide caused dissociation of hexokinase from
mitochondria will make the cells more vulnerable to the loss of
membrane potential caused by 3-BrPA, but the HKII dissociation itself
seems not affect mitochondria transmembrane potential. It is known
that the association of HKII withmitochondrial is signiﬁcantly affected
by its phosphorylation by Akt [21]. However, it is unclear at the
present time if 3-BrPA may cause a change in HKII phosphorylation
status. When protein extracts were incubated with phosphatase in
vitro, the up-shifted HKII band caused by 3-BrPA could not be shifted
down by the phosphatase digestion (data not shown), suggesting that
the band up-shifting was likely due to chemical modiﬁcation by 3-
BrPA, not by phosphorylation. Since the phosphatase incubation did
not cause a down-shift of HKII band, it is possible that the HKII
molecule from the 3-BrPA-treated cells was a in a dephosphorylated
form (could not be further dephosphorylated by phasphatase), and
thus was readily dissociated from mitochondria.
To further test if the dissociation of HKII from mitochondria may
inhibit respiration, the effect of N-HK II peptide on mitochondrial
oxidative phosphorylation and ROS generation was evaluated. Unlike
3-BrPA, N-HK II peptide alone had no effect on mitochondria
respiratory activity, although it can induce signiﬁcant cell death
(Fig. 6). HL-60 cells were incubated with 3–30 μM peptides for 3 h,
then oxygen consumption activity was measured using a Clark-type
oxygen electrode. Even high concentration (30 μM) of N-HK II
peptide did not show a signiﬁcant inhibition on mitochondria
respiration activity. It should be noted that apoptosis already occurred
even at 10 μM N-HK II peptide, as measured by annexin-V/PI staining
(Fig. 4).
The effect of N-HK II peptide on mitochondria ROS generation
was also tested. Superoxide level was measured using hydroethi-
dium (HEt) followed by ﬂow cytometry analysis. HL-60 cells were
incubated with various concentrations of peptide for 3 h, and
superoxide level was not affected even at toxic concentrations of the
peptide (Fig. 6B). Rotenone is a known inhibitor of mitochondrial
respiratory chain complex I and, as expected, promoted ROS
generation (Fig. 6C). Combination of rotenone with N-HK II peptide
did not further enhance superoxide generation caused by rotenone.
These data suggested that N-HK II peptide can cause dissociation of
HKII from mitochondria and lead to induction of apoptosis, but this
dissociation has no effect on mitochondria respiratory activity and
ROS generation.
Although the exact molecular mechanisms of Warburg effect still
remain to be elucidated, experimental evidences suggest that
upregulation of glycolysis in cancer cells not only ensures the
generation of ATP and other metabolic intermediate to meet the
need of cancer cells, it also renders resistance to apoptosis and survival
advantage compared to normal cells. These profound biochemical
alterations in metabolic proﬁle provide exciting opportunities for the
development of therapeutic strategies to preferentially kill cancer
cells.
As a potent inhibitor of hexokinase, 3-BrPA caused a mobility up-
shift of HKII protein band, which indicates a covalent modiﬁcation of
HKII. Our data also indicates that 3-BrPA may target the sulfhydryl
group of cysteine residues and this chemical modiﬁcation is
dependent on certain conformation of HKII. This covalent modiﬁca-
tion leads to the inhibition of hexokinase enzymatic activity and also
triggers its dissociation from mitochondria, which also contributes tocell death. Experiment with isolated mitochondria or intact cells
showed that the dissociation of HKII from the mitochondria induced
by 3-BrPA was coupled with a preferential release of AIF instead of
cytochrome c. The dissociation of HKII alone seems sufﬁcient to
trigger apoptosis. This is supported by the fact that N-HK II peptide
induced HKII dissociation and cell death, but did not cause alteration
in transmembrane potential and respiration.
Co-immunoprecipitation experiments suggest a possible existence
of a cross-membrane protein complex between HKII and AIF, which
can be disrupted by 3-BrPA. These ﬁndings provide new clues to
understand the function of both HKII and AIF inside the mitochondria
and how theymay affect each other. Although incubation of cells with
N-HK II peptide can directly cause cell death, the peptide did not show
other effects of 3-BrPA such as inhibition of mitochondria respiration
and decrease of mitochondria membrane potential. It seems that the
enzymatic activity of HKII may be important for energy metabolism,
while its mitochondria association may be important in regulation of
apoptosis. Targeting HKII may be an effective mean to kill cancer cells
and have potential clinical implications.
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